↓ Skip to main content

ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#14 of 321)
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
Published in
Journal of Experimental & Clinical Cancer Research, May 2015
DOI 10.1186/s13046-015-0139-4
Pubmed ID
Authors

Bailing Zu, Yi Shi, Min Xu, Guoling You, Zhenglan Huang, Miao Gao, Wenli Feng

Abstract

Treatment of blast phase chronic myeloid leukemia (BP-CML) remains a challenge, and the median survival is less than 6 months. Because effective treatments are lacking, we studied tight targeting of blast crisis CML cells using adenoviral (Ad) vectors expressing a HSV-TK system under dual control of a specific SUZ12 promoter and an antioxidant response element (ARE). A potential SUZ12 promoter fragment was designed with bioinformatics databases and identified with a luciferase assay. Next, we cloned the ARE element of the NQO1 gene and developed Ad vectors expressing TK kinase or luciferase under the dual control of a specific SUZ12 promoter and an ARE element. An in vitro transfection assay with Ad-ARE/SUZ12-Luc was used to determine promoter activity of ARE/SUZ12 regulatory element in blast crisis CML cells. After incubating human BP-CML-derived cells with Ad-ARE/SUZ12-TK and ganciclovir, Western blot, CCK8, Immunofluorescent assays and Annexin V assays were conducted to assess the efficacy of an ARE/SUZ12 dual-specific TK/GCV system for BP-CML cell lines. Here, luciferase data confirmed significantly higher and specificer promoter activity of the ARE/SUZ12 composite component in CML blast crisis-derived cell lines (K562, KCL22, and K562/G01) compared to HepG2 cells, and Ad-AS-TK/GCV system could exhibit enhanced apoptotic effects and decreased cell viability for BP-CML cell lines. Additionally, Ad-AS-TK/GCV system altered expression of cycle-related and apoptosis-related proteins in BP-CML cell lines. Thus, ARE/SUZ12 dual targeting TK/GCV system was effective in killing BP-CML cells. Moreover, efficacy and specificity of CML cell eradication were enhanced by synergistic effects of ARE/SUZ12 dual-specific regulation. We conclude that suicide gene-targeted therapy might hold promise for BP-CML treatment.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 13%
Student > Ph. D. Student 2 13%
Other 1 6%
Student > Doctoral Student 1 6%
Student > Master 1 6%
Other 2 13%
Unknown 7 44%
Readers by discipline Count As %
Medicine and Dentistry 4 25%
Biochemistry, Genetics and Molecular Biology 2 13%
Agricultural and Biological Sciences 1 6%
Immunology and Microbiology 1 6%
Engineering 1 6%
Other 0 0%
Unknown 7 44%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2015.
All research outputs
#730,064
of 5,153,949 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#14
of 321 outputs
Outputs of similar age
#34,470
of 173,105 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#2
of 23 outputs
Altmetric has tracked 5,153,949 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 321 research outputs from this source. They receive a mean Attention Score of 1.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,105 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.